NEKTAR THERAPEUTICS (NKTR)

Company Profile

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 216 full-time employees. The firm is focused on discovering and developing medicines in the field of immunotherapy. The firm has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Company Info

NEKTAR THERAPEUTICS

455 Mission Bay Boulevard South

San Francisco CALIFORNIA 94158

P: 14154825300

CEO: Howard W. Robin

Employees: 216

Website: https://www.nektar.com/